ALSA Ventures

Established in 2019 and based in London, ALSA Ventures is a life science venture capital investment firm with a focus on pharmaceutical &and biotechnology companies. The investor specializes in early stageearly-stage novel therapeutics.

On the 9th of May 2022, ALSA Ventures and Lonza, a development and manufacturing partner for pharma, biotech, and nutrition industries, reached a collaboration agreement to assist in developing and manufacturing biologics, as well as small molecule drug candidates catering to ALSA’s collection of pre-clinical plus early clinical biotechs.

In October 13, 2020, the investment firm launched Eclipse, a clinical development accelerator with a focus on therapeutics assets that are in late preclinical development. Through the framework, eligible establishments will be chosen for equity investment, as well as funding via the investor's inaugural fund called ALSA Ventures I SCSp. The applications will be analyzed quarterly on a competitive basis, with equity investment that is about $5M provided to awarded companies. After getting the investment, the selected companies will work with ICON, a clinical research organisationorganization in order to progress their asset via initial-in-man studies.

05.09.22On the 9th of May 2022, ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to thefor pharma, biotech and nutrition industries, have enteredreached a collaboration agreement to helpassist developin developing and manufacturemanufacturing biologics, as andwell as small molecule drug candidates forcatering to ALSA’s portfoliocollection of pre-clinical andplus early clinical biotechs.

October 13, 2020 in Technology and Engineering. ALSA Ventures, a London based European biotech investment firm today announced the launch of Eclipse, a novel clinical development accelerator focused on therapeutics assets in late preclinical development. Under the Eclipse framework, eligible companies will be selected for equity investment and funding through ALSA’s inaugural fund, ALSA Ventures I SCSp. Applications will be assessed on a competitive basis quarterly, with equity investment of up to $5M offered to awarded companies. Upon receipt of this investment, awarded companies will work with global clinical research organisation ICON to progress their asset through first-in-man studies.

In October 13, 2020, the investment firm launched Eclipse, a clinical development accelerator with a focus on therapeutics assets that are in late preclinical development. Through the framework, eligible establishments will be chosen for equity investment, as well as funding via the investor's inaugural fund called ALSA Ventures I SCSp. The applications will be analyzed quarterly on a competitive basis, with equity investment that is about $5M provided to awarded companies. After getting the investment, the selected companies will work with ICON, a clinical research organisation in order to progress their asset via initial-in-man studies.

FoundedEstablished in 2019 and based in London, ALSA Ventures is a life science venture capital investment firm basedwith a focus inon pharmaceutical London,& Unitedbiotechnology Kingdomcompanies. The firm seeks toinvestor investspecializes in companiesearly operatingstage innovel the life science, pharmaceutical & biotechnology sectorstherapeutics.

ALSA Ventures is a life science venture capital investor, focused on early stage novel therapeutics. With a strong operations background in drug development, our team seeks to bring together outstanding entrepreneurs and world class academic researchers to help bring promising new treatments to market. We invest across a wide spectrum of therapeutic areas, targeting high unmet need with impactful outcomes for patients and society at large.

October 13, 2020 in Technology and Engineering. ALSA Ventures, a London based European biotech investment firm today announced the launch of Eclipse, a novel clinical development accelerator focused on therapeutics assets in late preclinical development. Under the Eclipse framework, eligible companies will be selected for equity investment and funding through ALSA’s inaugural fund, ALSA Ventures I SCSp. Applications will be assessed on a competitive basis quarterly, with equity investment of up to $5M offered to awarded companies. Upon receipt of this investment, awarded companies will work with global clinical research organisation ICON to progress their asset through first-in-man studies.

05.09.22 ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered a collaboration agreement to help develop and manufacture biologics and small molecule drug candidates for ALSA’s portfolio of pre-clinical and early clinical biotechs.

October 13, 2020 in Technology and Engineering. ALSA Ventures, a London based European biotech investment firm today announced the launch of Eclipse, a novel clinical development accelerator focused on therapeutics assets in late preclinical development. Under the Eclipse framework, eligible companies will be selected for equity investment and funding through ALSA’s inaugural fund, ALSA Ventures I SCSp. Applications will be assessed on a competitive basis quarterly, with equity investment of up to $5M offered to awarded companies. Upon receipt of this investment, awarded companies will work with global clinical research organisation ICON to progress their asset through first-in-man studies.

October 13, 2020 in Technology and Engineering. ALSA Ventures, a London based European biotech investment firm today announced the launch of Eclipse, a novel clinical development accelerator focused on therapeutics assets in late preclinical development. Under the Eclipse framework, eligible companies will be selected for equity investment and funding through ALSA’s inaugural fund, ALSA Ventures I SCSp. Applications will be assessed on a competitive basis quarterly, with equity investment of up to $5M offered to awarded companies. Upon receipt of this investment, awarded companies will work with global clinical research organisation ICON to progress their asset through first-in-man studies.

Founded in 2019, ALSA Ventures is a venture capital investment firm based in London, United Kingdom. The firm seeks to invest in companies operating in the life science, pharmaceutical & biotechnology sectors.